1. Allen SG, Cummings J, Evans S, Nicholson M, Stewart ME, Cassidy J, Soukop M, Kaye SB, Smyth JF (1991) Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology. Cancer Chemother Pharmacol 28: 55–58
2. Calvert H, Smith I, Jones A, ten Bokkel Huinnink W, Hedley D, Francher D, Azarina N (1994) Phase II study of losoxantrone in previously treated and untreated patients with advanced breast cancer. Proc Am Soc Clin Oncol 13: 71
3. Coleman RE, Maisley MN, Knight RK, Rubens RD (1984) Mitoxantrone in advanced breast cancer – a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 20: 771–776
4. Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK (1999) A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. Clin Cancer Res 5: 299–308
5. Doroshow JH (1986) Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 135: 330–335